-
1
-
-
54949130573
-
Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations
-
Seo P., Specks U., Keogh K. A., Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations Journal of Rheumatology 2008 35 10 2017 2023
-
(2008)
Journal of Rheumatology
, vol.35
, Issue.10
, pp. 2017-2023
-
-
Seo, P.1
Specks, U.2
Keogh, K.A.3
-
2
-
-
0035674612
-
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy
-
DOI 10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W
-
Specks U., Fervenza F. C., McDonald T. J., Hogan M. C. E., Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis and Rheumatism 2001 44 12 2836 2840 (Pubitemid 34016203)
-
(2001)
Arthritis and Rheumatism
, vol.44
, Issue.12
, pp. 2836-2840
-
-
Specks, U.1
Fervenza, F.C.2
McDonald, T.J.3
Hogan, M.C.E.4
-
3
-
-
15044346440
-
Effective therapeutic use of rituximab in refractory Wegener's granulomatosis
-
DOI 10.1093/ndt/gfh599
-
Ferraro A. J., Day C. J., Drayson M. T., Savage C. O., Effective therapeutic use of rituximab in refractory Wegener's granulomatosis Nephrology Dialysis Transplantation 2005 20 3 622 625 (Pubitemid 40378435)
-
(2005)
Nephrology Dialysis Transplantation
, vol.20
, Issue.3
, pp. 622-625
-
-
Ferraro, A.J.1
Day, C.J.2
Drayson, M.T.3
Savage, C.O.4
-
4
-
-
12344330217
-
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis
-
DOI 10.1002/art.20718
-
Keogh K. A., Wylam M. E., Stone J. H., Specks U., Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis and Rheumatism 2005 52 1 262 268 (Pubitemid 40129256)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.1
, pp. 262-268
-
-
Keogh, K.A.1
Wylam, M.E.2
Stone, J.H.3
Specks, U.4
-
5
-
-
31944440872
-
Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial
-
DOI 10.1164/rccm.200507-1144OC
-
Keogh K. A., Ytterberg S. R., Fervenza F. C., Carlson K. A., Schroeder D. R., Specks U., Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial American Journal of Respiratory and Critical Care Medicine 2006 173 2 180 187 (Pubitemid 43187890)
-
(2006)
American Journal of Respiratory and Critical Care Medicine
, vol.173
, Issue.2
, pp. 180-187
-
-
Keogh, K.A.1
Ytterberg, S.R.2
Fervenza, F.C.3
Carlson, K.A.4
Schroeder, D.R.5
Specks, U.6
-
6
-
-
20144368363
-
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab
-
DOI 10.1111/j.1365-2796.2005.01494.x
-
Eriksson P., Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab Journal of Internal Medicine 2005 257 6 540 548 (Pubitemid 40776514)
-
(2005)
Journal of Internal Medicine
, vol.257
, Issue.6
, pp. 540-548
-
-
Eriksson, P.1
-
7
-
-
33745725917
-
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations
-
Aries P. M., Hellmich B., Voswinkel J., Both M., Nlle B., Holl-Ulrich K., Lamprecht P., Gross W. L., Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations Annals of the Rheumatic Diseases 2006 65 7 853 858
-
(2006)
Annals of the Rheumatic Diseases
, vol.65
, Issue.7
, pp. 853-858
-
-
Aries, P.M.1
Hellmich, B.2
Voswinkel, J.3
Both, M.4
Nlle, B.5
Holl-Ulrich, K.6
Lamprecht, P.7
Gross, W.L.8
-
8
-
-
0043074578
-
Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial
-
DOI 10.1002/art.11075
-
Stone J. H., Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial Arthritis and Rheumatism 2003 48 8 2299 2309 (Pubitemid 36959212)
-
(2003)
Arthritis and Rheumatism
, vol.48
, Issue.8
, pp. 2299-2309
-
-
Stone, J.H.1
|